Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

INTRODUCTION: The aim of this work is to evaluate treatment persistence and clinical outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. METHODS: Participants with PsA...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Ogdie, Alexis, Tesser, John, Shiff, Natalie J., Lin, Iris, Chakravarty, Soumya D., Kelleman, Michael, Dodge, Rhiannon, McLean, Robert R., Broadwell, Aaron, Kavanaugh, Arthur, Merola, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654277/
https://www.ncbi.nlm.nih.gov/pubmed/37597159
http://dx.doi.org/10.1007/s40744-023-00582-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654277/
https://www.ncbi.nlm.nih.gov/pubmed/37597159
http://dx.doi.org/10.1007/s40744-023-00582-w

Ejemplares similares